Welsh School of Pharmacy

Refereed Full Papers and Communications

Rapid and convenient thermal or microwave-assisted synthesis of substituted 2-phenylbenzothiazoles. Weekes AA, Dix MC, Bagley MC, Westwell AD. Synth. Comm. 2010, 40, 3027-3032.

Exploring the structural requirements for inhibition of the ubiquitin E3 ligase BCA2 as a treatment for breast cancer. Brahemi G, Kona FR, Fiasella A, Buac D, Soukupova J, Brancale A, Burger AM, Westwell AD. J. Med. Chem. 2010, 53, 2757-65.

Design, synthesis and pro-apoptotic antitumour properties of indole-based 3,5-disubstituted oxadiazoles. Ziedan NI, Stefanelli F, Fogli S, Westwell AD. Eur. J. Med. Chem. 2010, 45, 4523-4530.

Tuning the pH sensitivities of orthoester based compounds for drug delivery applications by simple chemical modification. Bruyere H, Westwell AD, Jones AT. Bioorg. Med. Chem. Lett. 2010, 20, 2200-03.

Cinnamaldehydes inhibit thioredoxin reductase and induce Nrf2: potential candidates for cancer therapy and chemoprevention. Chew E-H, Nagle AA, Zhang Y, Scarmagnani S, Palaniappan P, Bradshaw TD, Holmgren A, Westwell AD Free Rad. Biol. Med. 2010, 48, 98-111.

Homology modelling of human E1 ubiquitin activating enzyme. Brahemi G, Burger AM, Westwell AD, Brancale A. Lett. Drug Des. Discov. 2010, 7, 57-62.

Structure-activity analysis of 2’-modified cinnamaldehyde analogues as potential anticancer agents. Gan FF, Chua YS, Scarmagnani S, Palaniappan P, Franks M, Poobalasingam T, Bradshaw TD, Westwell AD, Hagen T. Biochem. Biophys. Res. Comm. 2009, 387, 741-747.

PMX464, a thiol-reactive quinol and putative thioredoxin inhibitor, inhibits NF-kappa B-dependent proinflammatory activation of alveolar epithelial cells. Callister ME, Pinhu L, Catley MC, Westwell AD, Newton R, Leaver SK, Quinlan GJ, Evans TW, Griffiths MJ, Burke-Gaffney A. Brit. J. Pharmacol. 2008, 155, 661-72.

Synthesis and biological properties of benzothiazole, benzoxazole, and chromen-4-one analogues of the potent antitumor agent 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610, NSC 721648). Aiello S, Wells G, Stone EL, Kadri H, Bazzi R, Bell DR, Stevens MFG, Matthews CS, Bradshaw TD, Westwell AD. J. Med. Chem. 2008, 51, 5135-5139.

2-[(1-methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation. Huber K, Patel P, Zhang L, Evans H, Westwell AD, Fischer PM, Chan S, Martin S. Mol. Cancer Ther. 2008, 7, 143-151.

Synthesis and antitumour evaluation of novel 2-phenylbenzimidazoles. Kadri H, Matthews CS, Bradshaw TD, Stevens MFG, Westwell AD. J. Enz. Inhib. Med. Chem. 2008, 23, 641-647.

Basal and angiotensin II-inhibited neuronal delayed-rectifier K+ current are regulated by thioredoxin. Matsuura T, Harrison RA, Westwell AD, Nakamura H, Martynyuk AE, Sumners C. Am. J. Physiol. Cell Physiol. 2007, 293, C211-C217.

Cannabinoid receptor agonists are mitochondrial inhibitors: a unified hypothesis of how cannabinoids modulate mitochondrial function and induce cell death. Athanasiou A, Clarke AB, Turner AE, Kumaran NM, Vakilpour S, Smith PA, Bagiokou D, Bradshaw TD, Westwell AD, Fang L, Lobo DN, Constantinescu CS, Calabrese V, Loesch A, Alexander SPH, Clothier RH, Kendall DA, Bates TE. Biochem. Biophys. Res. Comm. 2007, 364, 131-137.

Quinols as novel therapeutic agents. 7. Synthesis of antitumor 4-[1-(arylsulfonyl-1H-indol-2-yl)]-4-hydroxycyclohexa-2,5-dien-1-ones by Sonogashira reactions. McCarroll AJ, Bradshaw TD, Westwell AD, Matthews CS, Stevens MFG. J. Med. Chem. 2007, 50, 1707-1710.

Metabolically stabilized benzothiazoles for imaging of amyloid plaques. Henriksen G, Hauser AI, Westwell AD, Yousefi BH, Schwaiger M, Drzezga A, Wester H-J. J. Med. Chem. 2007, 50, 1087-1089.

Vannilloid receptor agonists and antagonists are mitochondrial inhibitors: how vanilloids cause non-vanilloid receptor mediated cell death. Athanasiou A, Smith PA, Vakilpour S, Kumaran NM, Turner AE, Bagiokou D, Layfield R, Ray DE, Westwell AD, Alexander SPH, Kendall DA, Lobo DN, Watson SA, Lophatanon A, Muir KA, Guo D, Bates TE. Biochem. & Biophys. Res. Comm. 2007, 354, 50-55.

Structure of Mycobacterium tuberculosis thioredoxin C. Hall G, Shah M, McEwan PA, Laughton C, Stevens M, Westwell A and Emsley J. Acta Crystallog. D, Biol. Crystallog. 2006, 62,  1453-1457.

Antitubercular properties of substituted hydroxycyclohexadienones. Shah M, Wells G, Bradshaw TD, Laughton CA, Stevens MFG, Westwell AD Lett. Drug Design and Discov. 2006, 3, 419-423.

Antitumour Properties of Fluorinated Benzothiazole-Substituted Hydroxycyclohexa-2,5-dienones (“Quinols”). Lion C.J, Matthews CS, Wells G, Bradshaw TD, Stevens MFG and Westwell AD Bioorg. & Med. Chem. Lett. 2006, 16, 5005-5008.

Antitumor quinols: role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets. Chew, E-H.; Matthews, C.S.; Zhang, J.; McCarroll, A.J.; Hagen, T.; Stevens, M.F.G.; Westwell, A.D.; Bradshaw, T.D. Biochem. Biophys. Res. Comm. 2006, 346, 242-251.

“Structural studies on bioactive compounds. 40. Synthesis and biological properties of fluoro-, methoxyl-, and amino-substituted 3-phenyl-4H-1-benzopyran-4-ones and a comparison of their antitumor activities with the activities of related 2-phenylbenzothiazoles” Vasselin DA, Westwell AD, Matthews CS, Bradshaw TD, Stevens MFG. J. Med. Chem. 2006, 49, 3973-3981.

“Antitumor Benzothiazoles. 26. 2-(3,4-Dimethoxyphenyl)-5-fluorobenzothiazole (GW 610, NSC 721648), a Simple Fluorinated 2-Arylbenzothiazole, shows Potent and Selective Inhibitory Activity against Lung, Colon, and Breast Cancer Cell Lines” Mortimer, C. G., Wells, G., Crochard, J-P., Stone, E. L., Bradshaw, T. D., Stevens, M. F. G. and Westwell, A. D. J. Med. Chem. 2006, 49, 179-185.

“Novel Reaction Products from the Hypervalent Iodine Oxidation of Hydroxylated Stilbenes and Isoflavones” Lion, C.J., Vasselin, D.A., Schwalbe, C.H., Matthews, C.S., Stevens, M.F.G. and Westwell, A.D. Org. Biomol. Chem. 2005, 3, 3996-4001.

“Elucidation of Thioredoxin as a Molecular Target for Antitumor Quinols” Bradshaw, T.D., Matthews, C.S., Cookson, J., Chew, E-H., Shah, M., Bailey, K., Monks, A., Harris, E., Westwell, A.D., Wells, G., Laughton, C.A. and Stevens, M.F.G. Cancer Research 2005, 65, 3911-3919.

“Synthesis, Antitumor Evaluation, and Apoptosis-Inducing Activity of Hydroxylated (E)-Stilbenes”
Lion, C.J., Matthews, C.S., Stevens, M.F.G. and Westwell, A.D. J. Med. Chem. 2005, 48, 1292-1295.

“Quinols as Novel Therapeutic Agents. 2. 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and Related Agents as Potent and Selective Antitumor Agents” Berry, J.M., Bradshaw, T.D., Fichtner, I., Ren, R., Schwalbe, C.H., Wells, G., Chew, E-H., Stevens, M.F.G. and Westwell, A.D. J. Med. Chem. 2005, 48, 639-644.

“Cytotoxic and anti-angiogenic activity of AW464 (NSC 706704), a novel thioredoxin inhibitor: An in vitro study” Mukherjee, A.; Bradshaw T.D.; Westwell A.D.; Stevens M.F.G.; Carmichael J.; Martin S.G. Brit. J. Cancer 2005, 92, 350-358.

“Induction of Apoptosis without Redox Catastrophe by Thioredoxin-Inhibitory Compounds”  Pallis, M., Bradshaw, T.D., Westwell, A.D., Grundy, M., Stevens, M.F.G. and Russell, N.H. Biochem. Pharmacol. 2003, 66, 1695-1705.

“Antitumor Benzothiazoles 23. Frontier Molecular Orbital Analysis Predicts Bioactivation of 2-(4-Aminophenyl)benzothiazoles to Reactive Intermediates by Cytochrome P4501A1” O’Brien, S.E., Browne, H.L., Bradshaw, T.D., Westwell, A.D., Stevens, M.F.G. and Laughton, C.A. Org. & Biomol. Chem.2003, 1, 493-497.

“4-Substituted-4-Hydroxycyclohexa-2,5-dien-1-ones with Selective Activities Against Colon and Renal Cancer Cell Lines” Wells, G., Berry, J.M., Bradshaw, T.D., Burger, A.M., Seaton, A., Wang, B., Westwell, A.D. and Stevens, M.F.G. J.Med.Chem. 2003, 46, 532-541.

“Antitumour Benzothiazoles. Part 20: 3´-Cyano and 3´-Alkynyl-Substituted 2-(4´-Aminophenyl)benzothiazoles as New Potent and Selective Analogues” Hutchinson, I., Bradshaw, T.D.; Matthews, C.S., Stevens, M.F.G. and Westwell, A.D. Bioorg. & Med. Chem. Lett. 2003, 13, 471-474.

“Antitumor Benzothiazoles. 16. Synthesis and Pharmaceutical Properties of Antitumor 2-(4-Aminophenyl)benzothiazole Amino Acid Prodrugs” Hutchinson, I., Jennings, S.A., Vishnuvajjala, B.R., Westwell, A.D. and Stevens, M.F.G. J. Med. Chem. 2002, 45, 744-747.

“A Revised Synthesis of the Antitumour Antibiotic L-Azatyrosine via 2-Iodo-5-methoxypyridine” Seton, A.W., Stevens, M.F.G. and Westwell, A.D. J. Chem. Res. (S) 2001, 546-548.

“Antitumour Benzothiazoles. Part 15. The Synthesis and Physico-Chemical Properties of 2-(4-Aminophenyl)benzothiazole Sulphamate Salt Derivatives” Shi, D-F., Bradshaw, T.D., Chua, M-S., Westwell, A.D. and Stevens, M.F.G. Bioorg. & Med. Chem. Lett. 2001, 11, 1093-1095.

“Antitumor Benzothiazoles. 14. The Synthesis and In Vitro Biological Properties of Fluorinated 2-(4-Aminophenyl)benzothiazoles” Hutchinson, I., Chua, M-S., Browne, H., Trapani, V., Fichtner, I., Bradshaw, T.D., Westwell, A.D. and Stevens, M.F.G. J. Med. Chem., 2001, 44, 1446-1455.

“Antitumour Benzothiazoles. 10. The Synthesis and Antitumour Activity of Benzothiazole Substituted Quinol Derivatives” Wells, G., Bradshaw, T.D., Diana, P., Seaton, A., Shi, D-F., Westwell, A.D. and Stevens, M.F.G. Bioorg. & Med. Chem. Lett., 2000, 10, 513-515.

“The Regiospecific Synthesis of 5- and 7-Monosubstituted and 5,6-Disubstituted 2-Arylbenzothiazoles,” Hutchinson, I., Stevens, M.F.G. and Westwell, A.D. Tetrahedron Lett., 2000, 41, 425-428.

"Antitumor Benzothiazoles.  8.  Synthesis, metabolic formation, and biological properties of the C- and N- oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles," Kashiyama, E., Hutchinson, I., Chua, M-S., Stinson, S.F., Phillips, L.R., Kaur, G., Sausville, E.A., Bradshaw, T.D., Westwell, A.D. and Stevens, M.F.G. J. Med. Chem., 1999, 42(20), 4172-4184.

"Auxiliary Accelerated Reactions: Towards the Use of Catalytic Enantiomerically Pure Auxiliaries," Westwell, A.D. and Williams, J.M.J. Tetrahedron, 1997, 53(38), 13063-13078.

"A Concise Synthesis of Either Enantiomer of Azatyrosine" Cooper, M.S., Seton, A.W., Stevens, M.F.G. and Westwell, A.D. Bioorg. Med. Chem. Lett.1996, 6, 2613-2616.

"Auxiliary Accelerated Reactions: Catalytic Hydrogenation," Westwell, A.D. and Williams, J.M.J., J. Chem. Soc., Perkin Trans. 1, 1996, 1-4.

"Homochiral 2,3-Epoxy Sulfides - Powerful New Synthetic Building Blocks Providing Stereoselective Access to 2,3-Epoxy Sulfoxides, 2,3-Dihydroxy Sulfoxides and (E)-g-Hydroxy-a,b-Unsaturated Sulfoxides and Sulfones," Westwell, A.D., Thornton-Pett, M. and Rayner, C.M., J. Chem. Soc., Perkin Trans. 1, 1995, 847-859.

"Auxiliary Accelerated Reactions: Transition-Metal Promoted Diels-Alder Cycloadditions," Westwell, A.D. and Williams, J.M.J., J. Chem. Soc., Chem. Comm., 1994, 2501-2502.

"Homochiral 2,3-Epoxy Sulfides as precursors to (E)-g-Hydroxy-a,b-Unsaturated Sulfoxides and Sulfones," Rayner, C.M. and Westwell, A.D., Tetrahedron : Asymm., 1994, 5, 355-358.

"Stereoselective Synthesis of 2,3-Epoxy Sulphoxides," Rayner, C.M., Sin, M.S. and Westwell, A.D., Tetrahedron Lett., 1992, 33, 7237-7240.

"Lewis Acid Induced Reaction of 2,3-Epoxy Phenylsulphoxides," Rayner, C.M. and Westwell, A.D., Tetrahedron Lett., 1992, 33, 2409-2412.

Review Articles

2-Arylbenzothiazole as a privileged scaffold in drug discovery. Weekes AA, Westwell AD. Curr. Med. Chem. 2009, 16, 2430-2440.

The development of pro-apoptotic cancer therapeutics. Ziedan NI, Kadri H, Westwell AD. Mini-Rev. Med. Chem. 2008, 8, 711-718.

Protein-protein interactions as targets for small-molecule therapeutics in cancer. White AW, Westwell AD, Brahemi G. Exp. Rev. Mol. Med. 2008, 10(8), 1-14.

The role of fluorine in medicinal chemistry. Shah P, Westwell AD. J. Enz. Inhibit. Med. Chem. 2007, 22(5), 527-540.

“Modulation of pRb/E2F Functions in the Regulation of the Cell Cycle and in Cancer” Seville, L.L., Shah, N., Westwell, A.D. and Chan, W.C. Current Cancer Drug Targets 2005, 5, 159-170.

"Update to: The Aryl hydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?" Bradshaw, T.D., Mortimer, C.G. and Westwell, A.D. Medicinal Chemistry Reviews – Online 2005, 2(2), 153-161.

“Hitting the chemotherapy jackpot: strategy, productivity and chemistry” Westwell, A.D. and Stevens, M.F.G. Drug Discovery Today (Editorial) 2004, 9(15), 625-627.

“The Therapeutic Potential of Aryl Hydrocarbon Receptor (AhR) Agonists in Anticancer Drug Development” Westwell, A.D. Drugs of the Future 2004, 29(5), 479-491.

“The Development of the Antitumour Benzothiazole Prodrug, Phortress, as a Clinical Candidate” Bradshaw, T.D. and Westwell, A.D. Curr. Med. Chem. 2004, 11, 1009-1021.

“The Arylhydrocarbon Receptor in Anticancer Drug Discovery: Friend or Foe?” Bradshaw, T.D., Trapani, V., Vasselin, D.A. and Westwell, A.D. Curr. Pharm. Des. 2002, 8, 2475-2490.

“The Discovery of the Potent and Selective Antitumour Agent 2-(4-Amino-3-methylphenyl)benzothiazole (DF 203) and Related Compounds” Bradshaw, T.D., Stevens, M.F.G. and Westwell, A.D. Current Medicinal Chemistry, 2001, 8, 203-210.

"L-Azatyrosine : a New Lead in Anticancer Drug Development" Stevens, M.F.G., Cooper, M.S. and Westwell, A.D. Drug Discovery Today 1996, 1, 401.

“Novel Antitumour Molecules” Drug Discovery Today; a regular contributor to the “Monitor” section of the journal. 38 articles to date (35 mini-reviews, 3 conference reviews).

Book Chapters

"The Chemistry of a,b-Unsaturated Sulphoxides," Rayner, C.M. and Westwell, A.D., in "Organosulfur Chemistry.  Synthetic and Stereochemical Aspects," Vol. 2, Ed. Page, P. Academic Press, 1998, pp. 157-228.

“Elimination and addition-elimination reactions” Westwell, A.D. and Williams, J.M.J. in "Preparation of Alkenes: A Practical Approach," Ed. Williams, J.M.J., Oxford University Press, 1996.

“Summary of alkene syntheses” Westwell, A.D. and Williams, J.M.J. in "Preparation of Alkenes: A Practical Approach," Ed. Williams, J.M.J., Oxford University Press, 1996.

Patents

 “4-(1-(Sulfonyl)-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-one compounds and analogues thereof as therapeutic agents and all related patent applications” Stevens, M.F.G.; Berry, J.; Wells, G.; Westwell, A.D.; Poole, T.D. PCT Application GB02/005842, published July 2004.

 “4-Aryl Quinols and Analogs Thereof as Therapeutic Agents” Stevens, M.F.G.; Wells, G.; Westwell, A.D.; Poole, T.D. PCT Application No. WO 03/004479 A1,publication date 16 January 2003.

“Substituted 2-Arylbenzazole Compounds and Their Use as Antitumour Agents” Stevens, M.F.G., Poole, T.D., Westwell, A.D., Hutchinson, I. and Chua, M-S. International Patent Number WO 01/14354 A1, publication Date: 1^st March 2001.

Published Conference Abstracts

Design and development of inhibitors of the ubiquitin E3 ligase BCA2. Buac D, Brahemi G, Xiong L, Fiasella A, Westwell AD, Seth AK, Burger AM. Proc. Amer. Assoc. Cancer Res. 2009, 50, 1360.

Advances in cancer drug discovery – a British Association for Cancer Research Meeting. Westwell AD. IDrugs 2008, 11, 783-786.

Design and synthesis of BCA2 inhibitors. Brahemi G, Fiasella A, Brancale A, Westwell A, Burger A. Eur. J. Cancer 2008, 6, S135.

Design and synthesis of novel indole derivatives as selective apoptosis-inducers. Ziedan NI, Westwell AD, Fogli S. Eur. J. Cancer 2008, 6, S141.

The design, synthesis and antitumour evaluation of novel small molecule inhibitors of the Dishevelled PDZ domain. Kadri H, Dale TC, Ewan KBR, Westwell AD. Eur. J. Cancer 2008, 6, S436.

The ubiquitin E3 ligase BCA2 is involved in the regulation of Rab7-mediated endocytic trafficking of the epidermal growth factor receptor (EGF-R) in breast cancer cells. Proc. Amer. Assoc. Cancer Res. 2008, 49, 32.

The anti-vascular properties of a novel thioredoxin inhibitor with anti-tubulin properties. Proc. Amer. Assoc. Cancer Res. 2008, 49, 87.

Cancer drug discovery through fluorous mixture synthesis of benzo-fused heterocycles. Weekes AA, Westwell AD. Targeted Oncology 2007, 2 (Suppl 1), S62.

“Development of metabolically stabilized 11C-labeled 2-(4-aminophenyl)benzothiazoles (BTAs) for imaging of amyloid plaques” Henriksen, G.; Westwell, A.; Hauser, A.; Manook, A.; Schwaiger, M.; Drzezga, A.; Wester, H. J. Nucl. Med. 2006, 47(Suppl S1), 32P.

“Thiol-interactive antitumor quinols as modulators of cellular redox homeostasis” Westwell, A.D.; Chew, E-H.; Zhang, J.H.; Matthews, C.S.; Hagen, T.; Bradshaw, T.D.; McCarroll, A.J.; Wells, G.; Stevens, M.F.G. Clin. Cancer Res. 2005, 11(24), 9147S.

“Chemical and structural studies on thioredoxin-inhibitory antitumour quinols” Westwell, A.D.; McCarroll, A.J.; Berry, J.M.; Ren, R.; Rathbone, D.L.; Lowe, P.R.; Schwalbe, C.H.; Burke, M.; Laughton, C.A.; Stevens, M.F.G. Eur. J. Cancer 2004, 2(8), 40.

“Preclinical evaluation of AW464 (NSC 706704), a novel thioredoxin inhibitor” Mukherjee, A.; Bradshaw T.D.; Westwell A.D.; Stevens M.F.G.; Carmichael J.; Martin S.G. Brit. J. Cancer 2004, 91 (Suppl. 1), S9.

“Identification of thioredoxin as a molecular target of arsenic trioxide as well as of calcitriol and the novel quinol AW 464: paradigms for chemotherapeutic strategies in APL and Multiple Myeloma” Pallis, M.; Bradshaw, T.D.; Westwell, A.D.; Grundy, M.; Stevens, M.F.G.; Russell, N.H. Blood 2003, 102, 597a.

“The thioredoxin inhibitor AW464 and the dithiol oxidant diamide induce apoptosis without accumulation of reactive oxygen species” Pallis, M., Bradshaw, T.D., Westwell, A.D., Grundy, M., Stevens, M.F.G., Russell, N.H. Leukemia 2003, 17, P25.

“Synthesis and Characterization of 2-(4-Amino-3-methylphenyl)benzothiazole-DNA adducts” Leong, C-O., O’Brien, S.E., Lion, C.J., Westwell, A.D., Laughton, C.A. and Stevens, M.F.G. Proc. Am. Assoc. Cancer Res. 2003, 44, #1644.

“In Vitro Antitumour and Antiangiogenic Activity of AW 464 (NSC 706704), a Novel Quinol” Mukherjee, A., Martin, S.G., Bradshaw, T.D., Westwell, A.D. and Carmichael, J. Brit. J. Cancer 2002, 86 (Suppl. 1), S108-S109.

“Novel Lead Antitumour Structures from Oxygenated and Hydroxylated Bicyclic Heterocycles” Wells, G., Berry, J.M., Bradshaw, T.D., Matthews, C.S., Stevens, M.F.G., Westwell, A.D. and Vasselin, D.A. Brit. J. Cancer 2002, 86 (Suppl. 1), S117.

“Synthesis of Heteroaromatic Quinols, Novel Agents with Selective Activity Clustered in Colon and Renal Cell Lines” Westwell, A.D., Wells, G., Berry, J.M., Bradshaw, T.D., Burger, A.M., Matthews, C.S., Monks, A. and Stevens, M.F.G. Proc. Am. Assoc. Cancer Res. 2002, 43, #1034.

“Use of the COMPARE Algorithm to Guide Mechanistic Studies on Novel Antitumor Agents – a Tale of Two Benazothiazoles” Stevens, M.F.G., Wells, G., Bradshaw, T.D., Westwell, A.D. and Holbeck, S.L. Proc. Am. Assoc. Cancer Res. 2002, 43, #4731.

“Mechanistic Studies and Evaluation of Clinical Markers for Phortress, a New Agent for Clinical Trials” Bradshaw, T.D., Browne, H.L., Hutchinson, I., Laughton, C.A., Leong, C.O., O’Brien, S., Stevens, M.F.G., Trapani, V. and Westwell, A.D. Brit. J. Cancer 2001, 85 (Suppl. 1), P272.

“Radiolabelling of the Potential Anti-Cancer Agent, 5-Fluoro-2-(4-amino-3-methylphenyl)benzothiazole (5F203) with Fluorine-18” Brown, G.D., Wilson, H.K., Westwell, A.D., Hutchinson, I., Stevens, M.F.G., Price, P.M., Aboagye, E., Luthra, S.K. and Brady, F. J. Labelled Cpds. and Radiopharmaceuticals 2001, 44 (Suppl. 1), S374-S375.

“Induction of CYP1A1 by 2-(4-Aminophenyl)benzothiazoles Leads to DNA Adducts in Sensitive Tumor Cells” Stevens, M.F.G., Heydon, R.T., Martin, E.A., Farmer, P.B., Bradshaw, T.D., Hutchinson, I., Westwell, A.D., Browne, H.L. and Trapani, V. Proc. Am. Assoc. Cancer Res., 2001, 42, 1754.

“Synthesis of Fluorinated 2-(4-Aminophenyl)benzothiazoles: A New Generation of Potent and Selective Antitumor Agents” Westwell, A.D., Hutchinson, I. and Stevens, M.F.G. Proc. Am. Assoc. Cancer Res., 2000, 41, 4884.

“Synthesis of Fluorinated 2-(4-Aminophenyl)benzothiazoles and their Prodrugs” Hutchinson, I., Stevens, M.F.G., Westwell, A.D. Clin. Cancer Res. 2000, 6, 152.

“Routes to Structural Diversity and Novel Antitumour Compounds from the Hypervalent Iodine Oxidation of Bioactive Phenols” Wells, G., Seaton, A., Westwell, A.D., Bradshaw, T.D., Stevens, M.F.G. Clin. Cancer Res. 2000, 6, 153.

“The Synthesis of Novel Heterocyclic Amino Acid Derivatives related in Structure to L-Azatyrosine, an anti-Ras Natural Product,” Seton, A.W., Stevens, M.F.G. and Westwell, A.D. Annals of Oncology, 1998, 9(S2), 122.